동종조혈모세포이식 환자에서 Tacrolimus와 Posaconazole 장용정 병용 시 Tacrolimus 용량 적절성 평가
Evaluation of Tacrolimus Dosage during Co-administration of Posaconazole Enteric-coated Tablet in Allogenic Hematopoietic Stem Cell Transplantation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : In allogenic hematopoietic stem-cell transplantation (HSCT), antifungal prophylaxis such as posaconazole is recommended to prevent invasive aspergillosis. However, blood concentration of tacrolimus is increased after taking it with posaconazole. The Ministry of Food and Drug Safety recommends the reduction of tacrolimus dose by one-third when receiving it with posaconzole. It was based on the study of posaconazole oral suspension. Thus, we evaluated the adequacy of tacrolimus dose adjustment when receiving it with posaconazole enteric-coated tablets in allogenic HSCT. Methods : From January 2020 to December 2021, a single-center and retrospective study was conducted on patients who received tacrolimus and posaconazole enteric-coated tablets together for more than 5 days after allogenic HSCT. We investigated the mean blood concentration of tacrolimus before and after combination with posaconazole. Patients were divided into two groups: those with decreased tacrolimus dose by less than 60% and those with decreased tacrolimus dose by more than 60%. Interaction rate, rate of out of effective therapeutic range, and incidence of Graft-versus-host-disease (GVHD) and nephrotoxicity were evaluated for the two groups. Results : Of 115 patients, the mean blood concentration of tacrolimus was significantly increased after receiving it with posaconazole (10.4 vs. 13.1 ng/mL, p < 0.0001). The interaction rate was significantly higher in the group of less than 60% reduction (37.9% vs. 19.3%, p=0.027). The rate of patients out of the effective therapeutic range was significantly different (37.2% vs. 25.5%, p = 0.018). The incidence of GVHD and nephrotoxicity were 68.7% and 71.3%, respectively. Conclusion : Tacrolimus blood concentration was significantly increased when it was administered with posaconzole after allogenic HSCT. The interaction rate and the rate out of effective therapeutic range were significantly higher in the group of tacrolimus dose reduction by less than 60%. Thus, preemptive dose adjustment is required when tacrolimus and posaconazole enteric-coated tablets are used together in allogenic HSCT.
Abstract
Background : In allogenic hematopoietic stem-cell transplantation (HSCT), antifungal prophylaxis such as posaconazole is recommended to prevent invasive aspergillosis. However, blood concentration of tacrolimus is increased after taking it with posaconazole. The Ministry of Food and Drug Safety recommends the reduction of tacrolimus dose by one-third when receiving it with posaconzole. It was based on the study of posaconazole oral suspension. Thus, we evaluated the adequacy of tacrolimus dose adjustment when receiving it with posaconazole enteric-coated tablets in allogenic HSCT. Methods : From January 2020 to December 2021, a single-center and retrospective study was conducted on patients who received tacrolimus and posaconazole enteric-coated tablets together for more than 5 days after allogenic HSCT. We investigated the mean blood concentration of tacrolimus before and after combination with posaconazole. Patients were divided into two groups: those with decreased tacrolimus dose by less than 60% and those with decreased tacrolimus dose by more than 60%. Interaction rate, rate of out of effective therapeutic range, and incidence of Graft-versus-host-disease (GVHD) and nephrotoxicity were evaluated for the two groups. Results : Of 115 patients, the mean blood concentration of tacrolimus was significantly increased after receiving it with posaconazole (10.4 vs. 13.1 ng/mL, p < 0.0001). The interaction rate was significantly higher in the group of less than 60% reduction (37.9% vs. 19.3%, p=0.027). The rate of patients out of the effective therapeutic range was significantly different (37.2% vs. 25.5%, p = 0.018). The incidence of GVHD and nephrotoxicity were 68.7% and 71.3%, respectively. Conclusion : Tacrolimus blood concentration was significantly increased when it was administered with posaconzole after allogenic HSCT. The interaction rate and the rate out of effective therapeutic range were significantly higher in the group of tacrolimus dose reduction by less than 60%. Thus, preemptive dose adjustment is required when tacrolimus and posaconazole enteric-coated tablets are used together in allogenic HSCT.
참고문헌 (25)
- 강형진, "조혈모세포이식의실제" (2016), 대한조혈모세포이식학회
- "2010 ISDA guideline, Clinical practice guideline for the use antimicrobial agent in neutropenic patient with cancer: 2010update guideline", ~
- "2016 Guidelines, Practice Guidelines for the Diagnosis and Management of Aspergillosis:2016 Update", Infectious Disease Society of America, ~
- 항진균제, , 2022
- Saad AH, "Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants", Pharmacotherapy, 26(12), pp.1730~1744 (2006)
- Groll AH, "Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4", Transpl Infect Dis, 19, pp.e12751~ (2017)
- Przepiorka D, "Practical considerations in the use of tacrolimus for allogeneic marrow transplantation", Bone Marrow Transplant, 24(10), pp.1053~1056 (1999)
- "Noxafil®(posaconazole) prescribing information" (2022)[URL]
- Berge M, "Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis", Ther Drug Monit, 31(3), pp.396~399 (2009)
- Jung DS, "Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity", Antimicrob Agents Chemother, 58(11), pp.6993~6995 (2014)
- Gu TM, "Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations", J Oncol Pharm Pract, 28(6), pp.1357~1362 (2022)
- Collins J, "The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation", J Oncol Pharm Pract, 26(1), pp.5~12 (2020)
- JM Morton, "Trough levels are inadequate for monitoring tacrolimus pharmacokinetics in lung transplantation", J Heart Lung Transplant, 21(1), pp.144~ (2002)
- Venkataramanan R, "Clinical pharmacokinetics of tacrolimus", Clin Pharmacokinet, 29(6), pp.404~430 (1995)
- Segal BH, "Aspergillosis", N Engl J Med, 360, pp.1870~1884 (2009)
- National Comprehensive Cancer Network, "NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer-Related Infections (NCCN Guidelines) Version1", ~ (2021)
- "Vfend®(voriconazole) prescribing information" (2023)[URL]
- Antiviral drugs advisory committee, F D A, "Briefing Document for Voriconazole(Oral and Intravenous Formulations)", US Food and Drug Administration, ~ (2001)
- Mikus G, "Pharmacogenomics of the triazole antifungal agent voriconazole", Pharmacogenomics, 12(6), pp.861~872 (2011)
- 김보배, "동종조혈모세포이식 시 Cyclosporine과Voriconazole 또는 Fluconazole의 약물상호작용 비교", 병원약사회지, 30(5), pp.426~438 (2013), 한국병원약사회[DOI]
- Sandherr M, "Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergilliosis – review of the literature", Eur J Med Res, 16(4), pp.139~144 (2011)
- Sanchez-Ortega I, "Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients", Antimicrob Agents Chemother, 56(12), pp.6422~6424 (2012)
- Gross BN, "Posaconazole Therapeutic Drug Monitoring in the Real-life Setting", Pharmacotherapy, 33(10), pp.1117~1125 (2013)
- Arai S, "Management of graft-versus-host disease", Blood Rev, 14(4), pp.190~204 (2000)
- Dekkers BGJ, "Therapeutic Drug Monitoring of Posaconazole : an Update", Curr Fungal Infect Rep, 10(2), pp.51~61 (2016)